All In Biotech

Drug Trial Radar · NCT06568094

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

An Open, Multicenter Phase Ib/II Study on the Safety, Tolerability and Efficacy of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Sep 25, 2024

Primary completion

Dec 2026

Study completion Jun 2027

Sponsor

Sponsor type
Industry
First posted
Aug 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, and safety of HRS-5041 tablets combined with antitumor therapy in subjects with advanced prostate cancer.

Conditions

  • Prostate Cancer

Interventions

  • HRS-5041 tabletsDrug

    HRS-5041 tablets

  • Abiraterone Acetate tablets(II)Drug

    Abiraterone Acetate tablets(II)

  • Prednisone Acetate tabletsDrug

    Prednisone Acetate tablets

  • Docetaxel InjectionDrug

    Docetaxel Injection

  • HRS-1167 tabletsDrug

    HRS-1167 tablets

  • SHR2554 tabletsDrug

    SHR2554 tablets

  • HRS-6208 capsulesDrug

    HRS-6208 capsules

  • HRS-2189 TabletsDrug

    HRS-2189 tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended phase II dose (Phase Ib)Time frame: 21 or 28 days
  2. Incidence and severity of adverse events (AE) (Phase Ib)Time frame: 2 years
  3. PSA response rate (Phase II)Time frame: 1 year

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China · Recruiting

  • Shanghai Jiao Tong University School of Medicine, Renji Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.